Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

In-process research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

New York, New York--(Newsfile Corp. - June 24, 2021) -  Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Ocugen, Inc. (NASDAQ: OCGN).CLICK HERE FOR MORE DETAILS:https://claimyourloss.com/securities/ocugen-inc-loss-submission-form/?id=17169&from=5

OCGN LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of Ocugen, Inc. Shareholders

New York, New York--(Newsfile Corp. - June 23, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Ocugen, Inc. (NASDAQ: OCGN) between February 2, 2021 and June 10, 2021, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than...

ROSEN, A LEADING LAW FIRM, Encourages Ocugen, Inc. Investors With Losses Exceeding $100K to Secure Counsel Before Important August 17 Deadline in Securities Class Action - OCGN

Bellerophon Therapeutics

Entera Bio Ltd

GT Biopharma Inc

Orphazyme A/S

Current & Former Penny Stocks To Watch Before July The post 8 Hot Biotech Penny Stocks For Your July 2021 Watch List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

8 Hot Biotech Penny Stocks For Your July 2021 Watch List

Boston, Massachusetts--(Newsfile Corp. - June 22, 2021) - Block & Leviton announces that a lawsuit for violations of federal securities laws has been filed against Ocugen, Inc. (NASDAQ: OCGN) and certain of its executives. Investors who have lost money in their Ocugen investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/ocgn.What is this all about?On June 10, 2021, Ocugen announced that it would "no...

Lawsuit Filed: Ocugen Sued for Violations of Federal Securities Laws; Investors Should Contact Block & Leviton

Ocugen Inc. (NASDAQ:OCGN) shares are trading lower Tuesday, likely making a correction after shares saw a nice gain Monday. Ocugen was down 5.14% at $7.02 at last check.

What's Next For Ocugen Stock As It Bounces Off Support?

NEW YORK, June 22, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ocugen, Inc.  ("Ocugen" or "the Company") (NASDAQ: OCGN) and certain of its directors on behalf of shareholders who purchased or otherwise acquired Ocugen securities between February 2, 2021 and June 2, 2021 (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/ocgn.

OCGN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Ocugen, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm

Investors need to pay close attention to Ocugen (OCGN) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Ocugen (OCGN) Stock?

The stock price of Ocugen Inc (NASDAQ: OCGN) increased by over 2% pre-market. This is why it happened.

OCGN Stock Price Increases Over 2% Pre-Market: Why It Happened

Snowflake

Tesla

A lower price won't address these other risks.

3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes

SAN DIEGO & MALVERN, Pa.--(BUSINESS WIRE)---- $OCGN #LawFirm--Shareholder rights law firm Robbins LLP announces that a class action has been filed on behalf of all purchasers of Ocugen, Inc. (NASDAQ: OCGN) who acquired Ocugen securities between February 2, 2021 and June 10, 2021. The complaint asserts claims under the Securities Exchange Act of 1934. Ocugen purports to be a biopharmaceutical company focused on developing gene therapies to cure blindness and developing vaccines to save lives from COVID-19. Ocugen'

SHAREHOLDER ALERT: Robbins LLP Announces That Ocugen, Inc. (OCGN) Is Being Sued for Misleading Shareholders

MALVERN, Pa., June 21, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that Ken Inchausti has joined the company as Head, Investor Relations & Communications. Mr. Inchausti will oversee the company's investor relations activities, corporate communications and strategic positioning, leading issues management strategy and proactive media and social media relations programming.

Ocugen, Inc. Announces Ken Inchausti as Head, Investor Relations & Communications

GameStop

Moderna

NVIDIA

Palantir Technologies

If analysts are correct, these high-flying stocks will fizzle out over the next year.

5 Ultra-Popular Stocks Wall Street Views as Overvalued

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Ocugen, Inc. (NASDAQ: OCGN) between February 2, 2021 and June 10, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 17, 2021. SO WHAT: If you purchased Ocugen securities during the Class Period you may be

ROSEN, A TOP RANKED LAW FIRM, Encourages Ocugen, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – OCGN

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed against Ocugen, Inc. (NASDAQ: OCGN) in the United States District Court for the Eastern District of Pennsylvania on behalf of those who purchased or otherwise acquired Ocugen publicly traded securities between February 2, 2021 and June 10, 2021, inclusive (the “Class Period”). Investors have until August 17, 2021 to apply to the Co

OCUGEN ALERT: Bragar Eagel & Squire, P.C. Is Investigating Ocugen, Inc. on Behalf of Ocugen Stockholders and Encourages Investors to Contact the Firm

NEW YORK, June 18, 2021 /PRNewswire/ -- WHY: New York, N.Y., June 18, 2021.

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline- OCGN

SAN DIEGO--(BUSINESS WIRE)-- #OCGNstock--The suit alleges defendants issued false statements concerning Ocugen's business and prospects, resulting in its stock trading at inflated prices.

Notice of Lead Plaintiff Deadline for Shareholders in the Ocugen, Inc. Class Action Lawsuit

New York, New York--(Newsfile Corp. - June 18, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Ocugen, Inc. ("Ocugen") (NASDAQ: OCGN) between February 2, 2021 and June 10, 2021, inclusive. You are hereby notified that the class action lawsuit Nicanor v. Ocugen, Inc., et al (2:21-cv-02725) has been commenced in the United States District Court for the...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Ocugen, Inc. Shareholders and Sets a Lead Plaintiff Deadline of August 17, 2021

Los Angeles, California--(Newsfile Corp. - June 18, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Ocugen announced on May 26, 2021, that it planned to submit an...

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ocugen, Inc. and Encourages Investors with Losses to Contact the Firm

Novavax

Can they keep outpacing the popular cryptocurrency?

2 Stocks That Are Running Circles Around Bitcoin This Year

Los Angeles, California--(Newsfile Corp. - June 17, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Ocugen announced on May 26, 2021, that it planned to submit an...

ONGOING INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Ocugen, Inc. and Encourages Investors with Losses to Contact the Firm

Ocugen (OCGN) selects Jubilant HollisterStier as its manufacturing partner for its COVID-19 vaccine candidate, Covaxin, in the United States and Canada.

Ocugen (OCGN) Selects Coronavirus Vaccine Manufacturer in US

Los Angeles, California--(Newsfile Corp. - June 16, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Ocugen announced on May 26, 2021, that it planned to submit an...

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Ocugen, Inc. and Encourages Investors with Losses to Contact the Firm

After the FDA rejected Covaxin, Ocugen has almost no chance of generating profits from the shot. OCGN stock is a great short.

It's Time to Admit Defeat and Dump Ocugen Stock as a Covid Play

MALVERN, Pa., June 16, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021, according to a preliminary list of additions posted June 4, 2021.

Ocugen Inc. Set to Join Russell 3000® Index

The stock price of Ocugen Inc (NASDAQ: OCGN) increased by 2.12% yesterday. This is why it happened.

News for Ocugen, Inc. Stock (OCGN)